Seattle, Washington, U.S., September 15, 2026
HDT Bio Corp. has received an ARPA-H GIVE award to lead the development of an automated, point-of-care manufacturing platform designed to support the rapid production of personalized RNA medicines. The award will support the company’s work on a new manufacturing approach intended to enable RNA-based therapeutics to be produced closer to the patient and potentially reduce the time and complexity associated with conventional centralized manufacturing. The initiative is focused on addressing key challenges in personalized medicine, where therapies may need to be manufactured in response to an individual patient’s specific disease characteristics. By combining automation, RNA manufacturing technologies, and point-of-care production, HDT Bio aims to develop a platform capable of supporting more flexible and responsive therapeutic manufacturing.
ARPA-H GIVE Program Targets RNA Manufacturing
The GIVE program, supported by the Advanced Research Projects Agency for Health (ARPA-H), is focused on developing innovative approaches that can improve the accessibility, scalability, and responsiveness of biomedical technologies. HDT Bio’s award will support the development of an automated manufacturing platform specifically designed for personalized RNA medicines. Traditional pharmaceutical manufacturing generally relies on centralized facilities capable of producing medicines at large scale. While this approach is effective for conventional products manufactured in standardized batches, personalized medicines can present different logistical and manufacturing requirements. Individualized RNA therapies may require rapid production of specific sequences or formulations, making manufacturing speed, flexibility, quality control, and scalability important considerations. HDT Bio’s proposed system seeks to address these challenges by integrating manufacturing steps into an automated platform that could potentially operate closer to the point of patient care. The objective is to establish a manufacturing process capable of producing personalized RNA medicines while maintaining appropriate quality and consistency.
Automated Point-of-Care Production
A major component of the initiative is the development of automated, point-of-care manufacturing. Rather than requiring every personalized therapeutic product to be manufactured at a distant centralized facility and subsequently transported to a treatment center, point-of-care manufacturing could allow production to occur closer to where patients receive treatment. Automation is expected to play an important role in this approach. Manufacturing personalized RNA medicines involves multiple controlled processes, including formulation, processing, quality assessment, and product handling. Integrating these activities into an automated system could potentially reduce manual intervention and improve process consistency. HDT Bio is developing the technology with the goal of creating a platform that can be deployed in clinical or healthcare environments. Such a system would need to address stringent requirements related to manufacturing quality, process control, sterility, reliability, and regulatory compliance before personalized medicines could be routinely manufactured and administered at the point of care. The development therefore represents not only an RNA therapeutic manufacturing project but also an effort to create new infrastructure for the future of personalized biopharmaceutical production.
Advertisement
Expanding Access to Personalized RNA Medicines
RNA technologies have become an increasingly important area of pharmaceutical research, with applications ranging from vaccines and protein replacement to gene regulation and individualized cancer treatments. However, manufacturing remains a significant consideration when therapeutic products must be customized for individual patients. The HDT Bio program is designed to explore whether automated manufacturing technology can help overcome some of these limitations. By developing a platform capable of producing RNA medicines in a more localized and potentially streamlined manner, the company aims to support applications where conventional large-scale manufacturing may not provide the required speed or flexibility.
The ARPA-H award provides resources for advancing the technology and evaluating whether the proposed manufacturing model can meet the technical requirements necessary for personalized therapeutic production. Successful development could provide a new approach for researchers and clinicians working with individualized RNA medicines. The initiative also highlights the growing intersection between drug development, advanced manufacturing, automation, and precision medicine. As therapeutic research increasingly moves toward treatments tailored to individual patients, manufacturing technologies will need to evolve alongside the medicines themselves. HDT Bio’s ARPA-H-supported program therefore represents an important development in personalized RNA medicine manufacturing. The project aims to create an automated point-of-care platform that could eventually help accelerate production and delivery of individualized RNA therapies. Further development, testing, and validation will be required to establish the platform’s performance and regulatory suitability, but the program demonstrates continued investment in technologies designed to make personalized medicines more practical and scalable.
Source: HDT Bio press release
